Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 15(3): e0229602, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32126572

RESUMO

AIM: This study analyzed microvesicles and exosomes, called as extracellular vesicles (EVs) excreted in serum and cerebrospinal fluid (CSF) from patients with cerebral or gestational toxoplasmosis. METHODS: Clinical samples from 83 individuals were divided into four groups. Group I, 20 sera from healthy individuals and pregnant women (seronegative for toxoplasmosis); group II, 21 sera from seropositive patients for toxoplasmosis (cerebral or gestational forms); group III, 26 CSF samples from patients with cerebral toxoplasmosis/HIV co-infection (CT/HIV) (seropositive for toxoplasmosis); and group IV, 16 CSF samples from seronegative patients for toxoplasmosis, but with HIV infection and other opportunistic infections (OI/HIV). Serum and CSF samples were ultracentrifuged to recover EVs. Next, vesicle size and concentration were characterized by Nanoparticle Tracking Analysis (NTA). RESULTS: Concentrations of serum-derived EVs from toxoplasmosis patients (mean: 2.4 x 1010 EVs/mL) were statically higher than of non-infected individuals (mean: 5.9 x 109 EVs/mL). Concentrations of CSF-derived EVs were almost similar in both groups. CT/HIV (mean: 2.9 x 109 EVs/mL) and OI/HIV (mean: 4.8 x 109 EVs/mL). Analyses by NTA confirmed that CSF-derived EVs and serum-derived EVs had size and shape similar to microvesicles and exosomes. The mean size of EVs was similar in serum and CSF. Thus, the concentration, and not size was able distinguish patients with toxoplasmosis than healthy individuals. Presence of exosomes was also confirmed by transmission electron microscopy and evidence of tetraspanins CD63 and CD9 in immunoblotting. Relative expressions of miR-146a-5p, miR-155-5p, miR-21-5p, miR-29c-3p and miR-125b-5p were estimated in exosomal miRNA extracted of EVs. Serum-derived EVs from group II (cerebral and gestational toxoplasmosis) up-expressed miR-125b-5p and miR-146a-5p. CSF-derived EVs from CT/HIV patients) up-expressed miR-155-5p and miR-21-5p and were unable to express miR-29c-3p. CONCLUSION: These data suggest the participation of EVs and exosomal miRNAs in unbalance of immune response as elevation of TNF-α, IL-6; and downregulation of IFN-γ in cerebral and gestational forms of toxoplasmosis.


Assuntos
Complicações Parasitárias na Gravidez/sangue , Complicações Parasitárias na Gravidez/líquido cefalorraquidiano , Toxoplasmose Cerebral/sangue , Toxoplasmose Cerebral/líquido cefalorraquidiano , Toxoplasmose/complicações , Micropartículas Derivadas de Células/genética , Micropartículas Derivadas de Células/patologia , Exossomos/genética , Exossomos/patologia , Vesículas Extracelulares/genética , Vesículas Extracelulares/patologia , Feminino , Expressão Gênica , Infecções por HIV/sangue , Infecções por HIV/líquido cefalorraquidiano , Infecções por HIV/complicações , Voluntários Saudáveis , Humanos , MicroRNAs/sangue , MicroRNAs/líquido cefalorraquidiano , MicroRNAs/genética , Microscopia Eletrônica de Transmissão , Gravidez , Complicações Parasitárias na Gravidez/genética , Toxoplasmose/sangue , Toxoplasmose/líquido cefalorraquidiano , Toxoplasmose Cerebral/genética
2.
J Reprod Med ; 38(9): 747-50, 1993 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8254603

RESUMO

A pregnant woman was diagnosed with central nervous system toxoplasmosis and human immunodeficiency virus infection. Diagnosis was made by evaluating computed tomography scan results and toxoplasma antibody titers. The patient was treated with pyrimethamine and sulfadiazine, with an excellent fetal outcome. She responded well to this regimen but developed a delayed exanthematous hypersensitivity reaction. Treatment with a substitute regimen resulted in a recurrence of symptoms, leaving undesirable neurologic deficits.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS , Anticorpos Antiprotozoários/sangue , Complicações Parasitárias na Gravidez , Resultado da Gravidez , Toxoplasma/imunologia , Toxoplasmose Cerebral , Infecções Oportunistas Relacionadas com a AIDS/sangue , Infecções Oportunistas Relacionadas com a AIDS/líquido cefalorraquidiano , Infecções Oportunistas Relacionadas com a AIDS/diagnóstico por imagem , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Adulto , Animais , Hipersensibilidade a Drogas/etiologia , Quimioterapia Combinada , Exantema/induzido quimicamente , Feminino , Humanos , Gravidez , Complicações Parasitárias na Gravidez/sangue , Complicações Parasitárias na Gravidez/líquido cefalorraquidiano , Complicações Parasitárias na Gravidez/diagnóstico por imagem , Complicações Parasitárias na Gravidez/tratamento farmacológico , Prognóstico , Pirimetamina/efeitos adversos , Pirimetamina/uso terapêutico , Recidiva , Sulfadiazina/efeitos adversos , Sulfadiazina/uso terapêutico , Tomografia Computadorizada por Raios X , Toxoplasmose Cerebral/sangue , Toxoplasmose Cerebral/líquido cefalorraquidiano , Toxoplasmose Cerebral/diagnóstico por imagem , Toxoplasmose Cerebral/tratamento farmacológico , Zidovudina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...